Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease

BACKGROUND: Continuous therapy targeting human epidermal growth factor receptor 2 (HER2) is recommended until disease progression for patients with HER2-overexpressing (HER2+) metastatic breast cancer. Prolonged stable disease has been observed with such maintenance therapy using trastuzumab, but th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Lauren, Lindquist, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341317/
https://www.ncbi.nlm.nih.gov/pubmed/30687062
http://dx.doi.org/10.1159/000494264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341317/
https://www.ncbi.nlm.nih.gov/pubmed/30687062
http://dx.doi.org/10.1159/000494264

Ejemplares similares